Understanding CYP2D6 interactions

Drug Discovery Today

Volumn 14, Issue 19-20, 2009, Pages 964-972

  de Groot, Marcel J ^a   Wakenhut, Florian ^a   Whitlock, Gavin ^a   Hyland, Ruth ^b  

^a World Wide Medicinal Chemistry (WWMC)   (United Kingdom)

^b Pharmacokinetics Dynamics and Metabolism ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTHIADIAZOLE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450 2D6; CYTOCHROME P450 2D6 INHIBITOR; CYTOCHROME P450 INHIBITOR; DEXTROMETHORPHAN; DRUG METABOLITE; HEME; NEUROLEPTIC AGENT; SIMVASTATIN; TAMOXIFEN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; CRYSTAL STRUCTURE; DNA POLYMORPHISM; DRUG CLEARANCE; DRUG DESIGN; DRUG EXCRETION; DRUG METABOLISM; DRUG RESEARCH; DRUG TOLERABILITY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME SUBSTRATE; HUMAN; IC 50; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MOLECULAR DYNAMICS; NONHUMAN; PHARMACOGENETICS; PREDICTION; PROTEIN INTERACTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY;

ANIMALS; BIOTRANSFORMATION; COMPUTER SIMULATION; COMPUTER-AIDED DESIGN; CYTOCHROME P-450 CYP2D6; DRUG DESIGN; DRUG INTERACTIONS; ENZYME INHIBITORS; HEME; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN CONFORMATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RISK ASSESSMENT; SUBSTRATE SPECIFICITY;

EID: 70349448421     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.07.005     Document Type: Review

References (77)

1. Nelson D.R., et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 12 (1993) 1-51
2. Nelson D.R., et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6 (1996) 1-42
3. Zhou S.-F., et al. Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development. Curr. Med. Chem. 16 (2009) 2661-2805
4. Williams J.A., et al. Drug-drug interactions for UDP-glucuronosyltransferase substrates: A pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab. Dispos. 32 (2004) 1201-1208
5. Hiratsuka M., and Mizugaki M. Genetic polymorphisms in drug-metabolizing enzymes and drug targets. Mol. Genet. Metabol. 73 (2001) 298-305
6. Aklillu E., et al. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J. Pharmacol. Exp. Ther. 278 (1996) 441-446
7. Mclellan R.A., et al. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 7 (1997) 187-191
8. Daly A.K., et al. Nomenclature for human CYP2D6 allelles. Pharmacogenetics 6 (1996) 193-201
9. Halling J., et al. Genetic predisposition to Parkinson's disease: CYP2D6 and HFE in the Faroe islands. Pharmacogenetics Genomics 18 (2008) 209-212
10. Rostami-Hodjegan A., et al. Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease. Pharmacogenetics 8 (1998) 227-238
11. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol. Sci. 25 (2004) 193-200
12. Strobl G.R., et al. Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modelling and inhibition studies. J. Med. Chem. 36 (1993) 1136-1145
13. Koymans L.M.H., et al. A predictive model for substrates of cytochrome P-450-debrisoquine (2D6). Chem. Res. Toxicol. 5 (1992) 211-219
14. de Groot M.J., et al. A refined substrate model for human cytochrome P450 2D6. Chem. Res. Toxicol. 10 (1997) 41-48
15. de Groot M.J., et al. Novel approach to predicting P450 mediated drug metabolism. The development of a combined protein and pharmacophore model for CYP2D6. J. Med. Chem. 42 (1999) 1515-1524
16. de Groot M.J., et al. A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. J. Med. Chem. 42 (1999) 4062-4070
17. Samer C.F. Cytochrome P450 2D6 genetic polymorphism: the rapid, the untrarapid, the intermediate and the slow. Med. Hyg. 62 (2004) 697-703
18. Ingelman-Sunberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenetics J. (2005) 6-13
19. Wijnen P.A., et al. The Prevalence and clinical relevance of cytochrome P450 polymorphisms. Aliment. Pharmacol. Ther. 26 (2007) 211-219
20. Mulder A.B., et al. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin. Pharm. Ther. 70 (2001) 546-551
21. Kirchheiner J., et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 9 (2004) 442-473
22. Chou W.H., et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. Clin. Pharmacokinet. 12 (2002) 453-470
23. Bijl M.J., et al. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in β-blocker users. Clin. Pharm. Ther. 85 (2009) 45-50
24. Beverage J.N., et al. CYP2D6 polymorphisms and the impact on tamoxifen therapy. J. Pharm. Sci. 96 (2007) 2224-2231
25. McGinnity D.F., et al. Integrated in vitro analysis for the in vivo prediction of cytochrome P450-mediated drug-drug interactions. Drug Metab. Dispos. 36 (2008) 1126-1134
26. Reese M.J., et al. An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction. Drug Metab. Dispos. 36 (2008) 1198-1201
27. Rowland M., and Matin S.B. Kinetics of drug-drug interactions. J. Pharmacokinetics Biopharm. 1 (1973) 553-567
28. Kanamitsu S., et al. Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm. Res. 17 (2000) 336-343
29. Obach R.S., et al. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J. Pharmacol. Exp. Ther. 316 (2006) 336-348
30. Wrighton S.A., et al. The human CYP3A subfamily: practical considerations. Drug Metab. Rev. 32 (2000) 339-361
31. Obach R.S., et al. In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin. Pharmacol. Ther. 78 (2005) 582-592
32. Jenkins K.M., et al. Automated high throughput ADME assays for metabolic stability and cytochrome P450 inhibition profiling of combinatorial libraries. J. Pharm. Biomed. Anal. 34 (2004) 989-1004
33. Gao F., et al. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50). J. Biomol. Screen. 7 (2002) 373-382
34. Moody G.C., et al. Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. Xenobiotica 29 (1999) 53-75
35. Weaver R., et al. Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation. Drug Metab. Dispos. 31 (2003) 955-966
36. Zientek M., et al. Development of an in vitro drug-drug interaction assay to simultaneously monitor five cytochrome P450 isoforms and performance assessment using drug library compounds. J. Pharmacol. Toxicol. Meth. 58 (2008) 206-214
37. Cohen L.H., et al. In vitro drug interactions of cytochrome p450: an evaluation of fluorogenic to conventional substrates. Drug Metab. Dispos. 31 (2003) 1005-1015
38. Williams J.A., et al. Reaction phenotyping in drug discovery: moving forward with confidence?. Curr. Drug Metab. 4 (2003) 527-534
39. Dickins M., et al. Modelling and simulation of pharmacokinetic aspects of cytochrome p450-based metabolic drug-drug interactions. In: Taylor J.B., and Triggle D.J. (Eds). Comprehensive Medicinal Chemistry II Vol. 5 (2007), Elsevier Ltd. 827-846
40. Crespi C.L. Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. In: Meyer U.A., and Testa B. (Eds). Advances in Drug Research (1995), Academic Press 179-235
41. Proctor N.J., et al. Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica 34 (2004) 151-178
42. Rostami-Hodjegan A., and Tucker G.T. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat. Rev. Drug Discov. 6 (2007) 140-148
43. Dickinson G.L., et al. Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application. J. Clin. Pharmacol. 47 (2007) 175-186
44. Williams P.A., et al. Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol. Cell. 5 (2000) 121-131
45. Koymans L.M.H., et al. A preliminary 3D model for cytochrome P450 2D6 constructed by homology model building. J. Comput. Aided Mol. Des. 7 (1993) 281-289
46. de Groot M.J., et al. A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102 and P450 108. Chem. Res. Toxicol. 9 (1996) 1079-1091
47. 450 2D6 based on homology modeling and NMR studies of substrate binding. Biochemistry 35 (1996) 4540-4550
48. Lewis D.F.V., et al. Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism. Xenobiotica 27 (1997) 319-340
49. Kirton S.B., et al. Impact of incorporating the CYP2C5 crystal structure into comparative models of cytochrome P450 2D6. Proteins Struct. Funct. Genet. 49 (2002) 216-231
50. Venhorst J., et al. Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities. J. Med. Chem. 46 (2003) 74-86
51. Rowland P., et al. Crystal structure of human cytochrome P450 2D6. J. Biol. Chem. 281 (2006) 7614-7622
52. Strobl G. Entwicklung von strukturmodellen für substrate und inhibitoren von cytochrom P-450IID1 mit hilfe von molecular modeling und in-vitro-hemmungsmessungen. GSF Forschungszentrum für Umwelt und Gesundheit GmbH. (1991)
53. Strobl G., and Wolff T. Structural models for inhibitors and substrates of cytochrome P-450IID6 based on molecular modeling analysis. In: Archakov A.I., and Bachmanova G.I. (Eds). Cytochrome P450 biochemistry and biophysics (1992), INCO-TNC Joint Stock Company 736-738
54. Manuscript in preparation
55. Wolff T., et al. Substrate specificity of human liver cytochrome P-450 debrisoquine hydroxylase probed using immunochemical inhibition and chemical modeling. Cancer Res. 45 (1985) 2116-2122
56. Meyer U.A., et al. The molecular mechanism of two common polymorphisms of drug oxidation. Evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica 16 (1986) 449-464
57. Islam S.A., et al. A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation. Carcinogenesis 12 (1991) 2211-2219
58. de Groot M.J., et al. Computer prediction and experimental validation of cytochrome P450-2D6 dependent oxidation of GBR 12909 (1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine). Drug Metab. Dispos. 23 (1995) 667-669
59. de Groot M.J., et al. Extension of a predictive substrate model for human cytochrome P4502D6. Xenobiotica 27 (1997) 357-368
60. Snyder R., et al. Three-dimensional quantitative structure activity relationship for Cyp2d6 substrates. Quant. Struct. Act. Relat. 21 (2002) 357-368
61. Ekins S., et al. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. Pharmacogenetics 9 (1999) 477-489
62. Ekins S., and Wrighton S.A. Application of in silico approaches to predicting drug-drug interactions. J. Pharmacol. Toxicol. Methods 45 (2001) 65-69
63. Ekins S., et al. Generation and validationof rapid computational filters for CYP2D6 and CYP3A4. Drug. Metab. Dispos. 31 (2003) 1077-1080
64. Balakin K.V., et al. Quantitative structure-metabolism relationship modeling of metabolic N-dealkylation reaction rates. Drug Metab. Dispos. 32 (2004) 1111-1120
65. Burton J., et al. Recursive partitioning for the prediction of cytochromes P450 2D6 and 1A2 inhibition: importance of the quality of the dataset. J. Med. Chem. 49 (2006) 6231-6240
66. Gleeson M.P., et al. Generation of in silico cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A4 inhibition QSAR models. J. Comput. Aided Mol. Des. 21 (2007) 559-573
67. Jensen B.F., et al. In silico prediction of cytochrome P450 2D6 and 3A4 inhibition using Gaussian kernel weighted k-nearest neighbor and extended connectivity fingerprints, including structural fragment analysis of inhibitors versus noninhibitors. J. Med. Chem. 50 (2007) 501-511
68. Sciabola S., et al. Pharmacophoric fingerprint method (TOPP) for 3D-QSAR modeling: application to CYP2D6 metabolic stability. J. Chem. Inf. Model. 47 (2007) 76-84
69. Appiah-Opong R., et al. Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues. Eur. J. Med. Chem. 43 (2008) 1621-1631
70. Roy P.P., and Roy K. QSAR studies of CYP2D6 inhibitor aryloxypropanolamines using 2D and 3D descriptors. Chem. Biol. Drug. Des. 73 (2009) 442-455
71. Kemp C.A., et al. Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition. J. Med. Chem. 47 (2004) 5340-5346
72. Keizers P.H., et al. Metabolic regio- and stereoselectivity of cytochrome P450 2D6 towards 3,4-methylenedioxy-N-alkylamphetamines: in silico predictions and experimental validation. J. Med. Chem. 48 (2005) 6117-6127
73. Vaz R.J., et al. A 3D-QSAR model for CYP2D6 inhibition in the aryloxypropanolamine series. Bioorg. Med. Chem. Lett. 15 (2005) 3815-3820
74. Gleeson M.P. Generation of a set of simple, interpretable ADMET rules of thumb. J. Med. Chem. 51 (2008) 817-834
75. McMasters D.R., et al. Inhibition of recombinant cytochrome P450 isoforms 2D6 and 2C9 by diverse drug-like molecules. J. Med. Chem. 50 (2007) 3205-3213
76. Wakenhut F., et al. N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors. Bioorg. Med. Chem. Lett. 18 (2008) 4308-4311
77. Boulet S.L., et al. Effect of hydroxylation and fluorination of aryloxy phenylpropanamine serotonin and norepinephrine reuptake inhibitors on CYP450 2D6 dependant metabolism. 228th ACS National Meeting. ACS (2004)